Drugs / OKN4395
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06789172 | Jan 2025 → Jul 2028 expected | colorectal cancer, dedifferentiated liposarcoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma +6 | Epkin | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OKN4395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789172 ↗ |
| Action | Inhibit | “a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors” NCT06789172 ↗ |
| Route | Oral | “OKN4395 oral dosing twice per day” NCT06789172 ↗ |